Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Tdap-IPV vs Tetanus Vaccine in Healthy Adults
DRKS00000180Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised trial of Adacel Polio in Tetanus, diphtheria, pertussis and 1 more (2 arms), sponsored by Sanofi. Primary endpoints: Immunogenicity of REPEVAX vs monovalent tetanus vaccine and Safety and tolerability of REPEVAX vs monovalent tetanus vaccine. Started Oct 2009; status: completed.
02
Drugs
Adacel Polio
03
Conditions
Tetanusdiphtheriapertussispoliomyelitis
Beyond the preview
Go deeper on DRKS00000180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00000180.